Polio Bulletin 2014 Issue No Week 25 (as of 23 Jun 2014)

Transcription

1 Non-polio AFP rate Cases with adequate specimens (%) HIGHLIGHTS T e c h n i c a l A d v i s o r y G r o u p m e e t i n g, Manila, June 2014 The 23rd meeting of the Technical Advisory Group (TAG) on Immunization and Vaccine-Preventable Diseases in the Western Pacific Region was held in Manila on June The TAG members noted that the Regional Office for the Western Pacific, Expanded Programme on Immunization worked in consultation with WHO country offices and Member States to finalize the Regional Framework for Implementation of the Global Vaccine Action Plan (GVAP), including the goal of maintaining polio-free status, and to submit this framework to the Regional Committee for the Western Pacific for its endorsement. During the 23rd TAG meeting, the draft plan, Polio Endgame in the Western Pacific Region, was noted as a resource to guide and support the implementation of polio endgame activities in the Region. The TAG welcomed the conclusion of the 19th Regional Commission for the Certification (RCC) of Poliomyelitis Eradication regarding the polio-free status of the Region. The TAG acknowledged the progress made at the country and regional level toward implementation of the polio endgame. This includes: a. dissemination of technical information including the November 2013 SAGE recommendations on inactivated polio vaccine (IPV) schedule, revised WHO position paper on polio vaccines, International Health Regulations (IHR) recommendations for travellers coming from polio infected countries, and other important resources; b. multiple advocacy and sensitization events which played a role in the initiation of the polio endgame plans in many countries; c. initiation of funding requirements discussions including results of the UNICEF IPV tender and the GAVI board decision; and d. IPV introduction dates planned for most countries, and registration of IPV nearly complete. CONTACT US Expanded Programme on Immunization Regional Office for the Western Pacific World Health Organization P.O. Box 2932, 1000 Manila, Philippines Phone: Fax: , WPR_EPIdata@wpro.who.int Web: Issue No Week 25 (as of 23 Jun 2014) Chart 1. Non-polio AFP rate and adequate specimen collection rate, * * AFP rate annualized as of week % Chart 3. Polio immunization status of AFP, % 60% 40% 20% 0% CHN KHM LAO MYS PHL PNG VNM CHN KHM LAO MYS PHL PNG VNM 3 doses 1-2 doses 0 doses Unknown 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Chart 2. Percent with pending classification > 90 days after onset, 2014 Chart 4. Percentage of samples received at the lab 3 days of collection, 2014 Note: Priority countries were selected for the charts. Official WHO acronyms have been used for abbreviation: CHN (China), KHM (Cambodia), LAO (Lao People s Democratic Republic), MYS (Malaysia), PHL (Philippines), PNG (Papua New Guinea), and VNM (Viet Nam). CHN KHM LAO MYS PHL PNG VNM 100% 80% 60% 40% 20% 0% 0.0% 10.5% 15.9% 14.3% 17.1% 25.0% 57.1% 0% 10% 20% 30% 40% 50% 60% 53% 0% 0% 58% 28% 0% 42% CHN KHM LAO MYS PHL PNG VNM

2 Table 1A. Classification of AFP with onset in 2013 and key surveillance indicators 2012 Classification 2013 Indicators Annual expected <15 years of age Confirmed wild poliovirus Poliocompatible Vaccinederived poliovirus () Discarded (Non-polio) > 90 days 1 # (%) Non-polio AFP rate % with adequate specimens 2 % with any specimen 3 % investigated 2 days of notification 4 % with 60-day follow-up 5 Latest report date 6 Days since last report % 80% 80% Australia (0.0%) % 71% 100% 0% 08-Apr-14 - Brunei Darussalam (0.0%) % 100% 100% - 06-Feb-14 - Cambodia (0.0%) % 96% 78% 100% 13-Mar-14 - China (0.0%) % 99% 100% 98% 28-May-14 - Hong Kong (China) (0.0%) % 100% 100% - 06-Feb-14 - Japan Lao People's Democratic Republic (0.0%) % 90% 98% 100% 26-May-14 - Macao (China) (0.0%) % 100% 100% - 14-Jan-14 - Malaysia (0.0%) % 100% 85% 100% 31-Mar-14 - Mongolia (0.0%) % 100% 100% 100% 07-Mar-14 - New Zealand (0.0%) % 83% 83% 100% 27-Feb-14 - Papua New Guinea (0.0%) % 83% 83% 100% 26-Feb-14 - Philippines (0.0%) % 96% 98% 50% 08-Apr-14 - Republic of Korea (0.0%) % 100% 94% 100% 20-Mar-14 - Singapore (0.0%) % 100% 86% 100% 08-Jan-14 - Viet Nam (0.0%) % 99% 92% 100% 17-Apr-14 - Pacific island countries (12.5%) % 100% 100% 67% 14-May (0.0%) % 99% 98% 86% 1. Number (%) of pending classification more than 90 days from date of onset of paralysis to date of last report Green Reached or surpassed target 2. Percentage of with two stool specimens collected 24 hours apart and within 14 days of onset of paralysis Yellow Nearly reached target: for non-polio AFP rate; 60 79% for other indicators 3. Percentage of with at least one specimen Red Substantially below target 4. Percentage of investigated within two days of notification 5. Percentage of with inadequate specimens followed-up within 60 days of onset of paralysis 6. Report date is fixed as soon as all for the year have been classified 7. Countries are expected to submit data at least once per month to WPRO 2

3 Table 1B. Classification of AFP with onset in 2014 and key surveillance indicators 2013 Classification 2014 Indicators Annual expected <15 years of age Confirmed wild poliovirus Poliocompatible Vaccinederived poliovirus () Discarded (Non-polio) > 90 days 1 # (%) Non-polio AFP rate 2 % with adequate specimens 3 % with any specimen 4 % investigated 2 days of notification 5 % with 60-day follow-up 6 Latest report date Days since last report % 80% 80% Australia (10.5%) % 58% 84% 0% 23-May Brunei Darussalam Feb Cambodia (25.0%) % 100% 100% 0% 02-May China (17.1%) % 98% 100% 71% 19-Jun-14 4 Hong Kong (China) (12.5%) % 100% 100% 100% 03-Jun Japan Lao People's Democratic Republic (0.0%) % 100% 91% 0% 06-May Macao (China) (0.0%) % 100% 100% 100% 12-Jun Malaysia (10.5%) % 100% 55% 32% 20-Jun-14 3 Mongolia (0.0%) % 100% 100% - 09-Jun New Zealand (50.0%) % 100% 100% 0% 16-May Papua New Guinea (57.1%) % 100% 57% 0% 13-Jun Philippines (15.9%) % 93% 95% 3% 12-May Republic of Korea (0.0%) % 100% 95% 88% 19-Jun-14 4 Singapore (0.0%) % 100% 100% 100% 03-Jun Viet Nam (14.3%) % 100% 88% 0% 26-May Pacific island countries (80.0%) % 60% 60% 0% 16-Jun (16.5%) % 98% 97% 52% 1. Number (%) of pending classification more than 90 days from date of onset of paralysis to date of last report Green Reached or surpassed target 2. Annualized non-polio AFP rate per population under 15 years of age Yellow Nearly reached target: for non-polio AFP rate; 60 79% for other indicators 3. Percentage of with two stool specimens collected 24 hours apart and within 14 days of onset of paralysis Red Substantially below target 4. Percentage of with at least one specimen 5. Percentage of investigated within two days of notification 6. Percentage of with inadequate specimens followed-up within 60 days of onset of paralysis 7. Countries are expected to submit data at least once per month to WPRO 3

4 Country National polio laboratory 1 no. of AFP with specimens Table 2A. Laboratory investigation of AFP with onset in 2013 and key laboratory indicators L20B L20B + NPEV NPEV only Virus isolation results Negative 14 days > 14 days % results 14 days 2 % specimens for NPEV Latest report date Intratypic differentiation / Sequencing lab 1 No. of Type 1 isolates referred Wild Sabin 80% 80% Australia VIDRL % 20% 29-Jan-14 VIDRL Brunei Darussalam VIDRL % 0% 29-Jan-14 VIDRL Papua New Guinea VIDRL % 16% 29-Jan-14 VIDRL Pacific island countries VIDRL % 44% 29-Jan-14 VIDRL Japan NIID NIID Cambodia NIID % 24% 12-Feb-14 NIID % Lao People's Democratic Republic NIID % 21% 02-Apr-14 NIID Malaysia IMR % 3% 25-Feb-14 IMR Mongolia PHI % 14% 11-Feb-14 NIID New Zealand IESR % 22% 17-Mar-14 IESR Philippines RITM % 9% 08-May-14 VIDRL % Republic of Korea NIH % 3% 18-Feb-14 NIID Singapore SGH % 0% 15-Jan-14 SGH % Viet Nam, North NIHE % 15% 11-Feb-14 NIID % Viet Nam, South PI % 9% 18-Mar-14 NIID % China CCDC % 9% 14-May % China, Anhui Prov. Lab % 11% Prov. Lab % China, Beijing Prov. Lab % 0% Prov. Lab % China, Fujian Prov. Lab % 7% Prov. Lab % China, Gansu Prov. Lab % 5% Prov. Lab % China, Guangdong Prov. Lab % 8% Prov. Lab % China, Guangxi Prov. Lab % 9% Prov. Lab % China, Hebei Prov. Lab % 13% Prov. Lab % China, Heilongjiang Prov. Lab % 5% Prov. Lab % China, Henan Prov. Lab % 14% Prov. Lab % China, Hunan Prov. Lab % 13% Prov. Lab % China, Jiangsu Prov. Lab % 2% Prov. Lab % China, Jiangxi Prov. Lab % 7% Prov. Lab % China, Jilin Prov. Lab % 5% Prov. Lab China, Shaanxi Prov. Lab % 2% Prov. Lab China, Shandong Prov. Lab % 6% Prov. Lab % China, Shanghai Prov. Lab % 0% Prov. Lab % China, Shanxi Prov. Lab % 4% Prov. Lab % China, Sichuan Prov. Lab % 10% Prov. Lab China, Tianjin Prov. Lab % 4% Prov. Lab % China, Xinjiang Prov. Lab % 6% Prov. Lab % China, Yunnan Prov. Lab % 10% Prov. Lab % China, Zhejiang Prov. Lab % 9% Prov. Lab % China, Chongqing Prov. Lab % 9% CCDC China, Guizhou Prov. Lab % 9% CCDC % China, Hainan Prov. Lab % 11% CCDC % China, Hubei Prov. Lab % 13% CCDC % China, Liaoning Prov. Lab % 11% CCDC % China, Neimongol Prov. Lab % 4% CCDC % China, Ningxia Prov. Lab % 0% CCDC % China, Qinghai Prov. Lab % 3% CCDC China, Tibet Prov. Lab % 0% CCDC Hong Kong (China) PHLC % 0% 16-Jan-14 PHLC Macao (China) PHLC Jan-14 PHLC % 9% % 1. IESR (Institute of Environmental Science and Research, New Zealand); IMR (Institute of Medical Research, Malaysia); NIH (National Institute of Health, Republic of Korea); NIHE (National Institute of Hygiene and Epidemiology, Ha Noi, Viet Nam); NIID (National Institute of Infectious Diseases, Japan); PHI (Public Health Institute, Mongolia); PHLC (Public Health Laboratory Center, Hong Kong); PI (Pasteur Institute, Ho Chi Minh, Viet Nam); RITM (Research Institute for Tropical Medicine, Philippines); SGH (Singapore General Hospital); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia) 2. The target of 14 days for the timeliness of virus isolation will be used for all polio laboratories 3. NPEV growing in L20B cells 4. Twenty-two provincial laboratories in China perform from 2013 Wild Type 2 Sabin Intratypic differentiation () results Wild Type 3 Sabin NPEV 3 Discordant pending sequencing % results 7 days of receipt 4

5 Country National polio laboratory 1 no. of AFP with specimens Table 2B. Laboratory investigation of AFP with onset in 2014 and key laboratory indicators L20B L20B + NPEV NPEV only Virus isolation results Negative 14 days > 14 days % results 14 days 2 % specimens for NPEV Latest report date Intratypic differentiation / Sequencing lab 1 No. of Type 1 isolates referred Wild Sabin 80% 80% Australia VIDRL % 0% 14-Mar-14 VIDRL Brunei Darussalam VIDRL Mar-14 VIDRL Papua New Guinea VIDRL Mar-14 VIDRL Pacific island countries VIDRL % 0% 14-Mar-14 VIDRL Japan NIID NIID Cambodia NIID % 6% 27-May-14 NIID % Lao People's Democratic Republic NIID % 18% 16-Jun-14 NIID Malaysia IMR % 2% 11-Jun-14 IMR Mongolia PHI % 0% 05-Jun-14 NIID New Zealand IESR % 50% 03-Jun-14 IESR Philippines RITM % 3% 30-May-14 VIDRL Republic of Korea NIH % 0% 19-Jun-14 NIID Singapore SGH % 0% 30-May-14 SGH Viet Nam, North NIHE % 17% 12-Jun-14 NIID Viet Nam, South PI % 13% 03-Jun-14 NIID China CCDC % 6% 19-Jun % China, Anhui Prov. Lab % 0% Prov. Lab China, Beijing Prov. Lab % 0% Prov. Lab % China, Fujian Prov. Lab % 10% Prov. Lab China, Gansu Prov. Lab % 2% Prov. Lab % China, Guangdong Prov. Lab % 10% Prov. Lab % China, Guangxi Prov. Lab % 17% Prov. Lab % China, Hebei Prov. Lab % 7% Prov. Lab % China, Heilongjiang Prov. Lab % 1% Prov. Lab China, Henan Prov. Lab % 8% Prov. Lab % China, Hunan Prov. Lab % 11% Prov. Lab % China, Jiangsu Prov. Lab % 2% Prov. Lab % China, Jiangxi Prov. Lab % 7% Prov. Lab China, Jilin Prov. Lab % 0% Prov. Lab China, Shaanxi Prov. Lab % 5% Prov. Lab China, Shandong Prov. Lab % 3% Prov. Lab % China, Shanghai Prov. Lab % 0% Prov. Lab % China, Shanxi Prov. Lab % 0% Prov. Lab % China, Sichuan Prov. Lab % 9% Prov. Lab % China, Tianjin Prov. Lab % 17% Prov. Lab China, Xinjiang Prov. Lab % 2% Prov. Lab % China, Yunnan Prov. Lab % 9% Prov. Lab % China, Zhejiang Prov. Lab % 6% Prov. Lab % China, Chongqing Prov. Lab % 6% CCDC % China, Guizhou Prov. Lab % 7% CCDC % China, Hainan Prov. Lab % 25% CCDC China, Hubei Prov. Lab % 13% CCDC China, Liaoning Prov. Lab % 1% CCDC % China, Neimongol Prov. Lab % 1% CCDC China, Ningxia Prov. Lab % 0% CCDC China, Qinghai Prov. Lab % 0% CCDC China, Tibet Prov. Lab % 0% CCDC Hong Kong (China) PHLC % 0% 28-May-14 PHLC Macao (China) PHLC May-14 PHLC % 6% % 1. IESR (Institute of Environmental Science and Research, New Zealand); IMR (Institute of Medical Research, Malaysia); NIH (National Institute of Health, Republic of Korea); NIHE (National Institute of Hygiene and Epidemiology, Ha Noi, Viet Nam); NIID (National Institute of Infectious Diseases, Japan); PHI (Public Health Institute, Mongolia); PHLC (Public Health Laboratory Center, Hong Kong); PI (Pasteur Institute, Ho Chi Minh, Viet Nam); RITM (Research Institute for Tropical Medicine, Philippines); SGH (Singapore General Hospital); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia) 2. The target of 14 days for the timeliness of virus isolation will be used for all polio laboratories 3. NPEV growing in L20B cells 4. Twenty-two provincial laboratories in China perform from 2013 Wild Type 2 Sabin Intratypic differentiation () results Wild Type 3 Sabin NPEV 3 Discordant pending sequencing % results 7 days of receipt 5

6 Country Intratypic differentiation lab 2 number of non-afp tested for polio number of non-afp with polio isolates Table 3A. Laboratory confirmation of polio isolates from other sources in Non-AFP number Type 1 Type 2 Type 3 NPEV Discordant number Type 1 Type 2 Type 3 of samples grown pending of samples with polio Wild Sabin Wild Sabin Wild Sabin in L20B sequencing processed isolates Wild Sabin Wild Sabin Wild Sabin Australia VIDRL Japan NIID Malaysia IMR Mongolia PHI New Zealand IESR Philippines VIDRL Republic of Korea NIID Singapore SGH Viet Nam, North NIID Viet Nam, South NIID China (total) China, Anhui Prov. Lab China, Beijing Prov. Lab China, Fujian Prov. Lab China, Gansu Prov. Lab China, Guangdong Prov. Lab China, Guangxi Prov. Lab China, Hebei Prov. Lab China, Heilongjiang Prov. Lab China, Henan Prov. Lab China, Hunan Prov. Lab China, Jiangsu Prov. Lab China, Jiangxi Prov. Lab China, Jilin Prov. Lab China, Shaanxi Prov. Lab China, Shandong Prov. Lab China, Shanghai Prov. Lab China, Shanxi Prov. Lab China, Sichuan Prov. Lab China, Tianjin Prov. Lab China, Xinjiang Prov. Lab China, Yunnan Prov. Lab China, Zhejiang Prov. Lab China, Chongqing CCDC China, Guizhou CCDC China, Hainan CCDC China, Hubei CCDC China, Liaoning CCDC China, Neimongol CCDC China, Ningxia CCDC China, Qinghai CCDC China, Tibet CCDC Hong Kong (China) PHLC Based on year of collection of sample, if available. Otherwise, based on year of receipt at reference laboratory. Environmental samples 2. CCDC (Chinese Center for Disease Control and Prevention, China); IESR (Institute of Environmental Science and Research, New Zealand); IMR (Institute of Medical Research, Malaysia); NIID (National Institute of Infectious Diseases, Japan); PHI (Public Health Institute, Mongolia); PHLC (Public Health Laboratory Center, Hong Kong); SGH (Singapore General Hospital); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia) NPEV grown in L20B Discordant pending sequencing 6

7 Table 3B. Laboratory confirmation of polio isolates from other sources in Non-AFP Environmental samples Intratypic number number number Country differentiation Type 1 Type 2 Type 3 NPEV Discordant number Type 1 Type 2 Type 3 NPEV Discordant of non-afp of non-afp tested grown pending of samples of samples lab 2 grown pending with with polio Wild Sabin Wild Sabin Wild Sabin in L20B sequencing processed for polio polio isolates isolates Wild Sabin Wild Sabin Wild Sabin in L20B sequencing Australia VIDRL Japan NIID Malaysia IMR Mongolia PHI New Zealand IESR Philippines VIDRL Republic of Korea NIID Singapore SGH Viet Nam, North NIID Viet Nam, South NIID China (total) China, Anhui Prov. Lab China, Beijing Prov. Lab China, Fujian Prov. Lab China, Gansu Prov. Lab China, Guangdong Prov. Lab China, Guangxi Prov. Lab China, Hebei Prov. Lab China, Heilongjiang Prov. Lab China, Henan Prov. Lab China, Hunan Prov. Lab China, Jiangsu Prov. Lab China, Jiangxi Prov. Lab China, Jilin Prov. Lab China, Shaanxi Prov. Lab China, Shandong Prov. Lab China, Shanghai Prov. Lab China, Shanxi Prov. Lab China, Sichuan Prov. Lab China, Tianjin Prov. Lab China, Xinjiang Prov. Lab China, Yunnan Prov. Lab China, Zhejiang Prov. Lab China, Chongqing CCDC China, Guizhou CCDC China, Hainan CCDC China, Hubei CCDC China, Liaoning CCDC China, Neimongol CCDC China, Ningxia CCDC China, Qinghai CCDC China, Tibet CCDC Hong Kong (China) PHLC Based on year of collection of sample, if available. Otherwise, based on year of receipt at reference laboratory. 2. CCDC (Chinese Center for Disease Control and Prevention, China); IESR (Institute of Environmental Science and Research, New Zealand); IMR (Institute of Medical Research, Malaysia); NIID (National Institute of Infectious Diseases, Japan); PHI (Public Health Institute, Mongolia); PHLC (Public Health Laboratory Center, Hong Kong); SGH (Singapore General Hospital); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia) 7

8 Table 4. Vaccine-derived poliovirus, Country Cambodia c3 (1 case) c3 (1 case) China Hong Kong (China) a1 (1 case) i1 (1 case) a3 (1 case) a1 (1 case) a3 (1 case) c1 (2 )?1 (4 )?2 (1 case) i2 (1 case)?? (3 ) a1 (1 case) a1 (3 )?1 (7 )?1 (1 case) 3 (1 case) a2 (1 case) a2 (5 ) a3 (2 ) a1 (1 case) a2 (3 ) c2 (2 ) i2 (2 ) i3 (1 case) a1 (1 case) a2 (2 ) c2 (3 ) i2 + i3 (1 case) a2 (1 case) i2 + i3 (1 case) Japan?? (1 case)?3 (1 case) Lao People's Democratic Republic Mongolia?? (1 case) a2 (1 case)?? (2 ) Philippines c1 (3 ) Viet Nam a2 (2 ) 8